Korro Bio (KRRO) Consolidated Net Income (2018 - 2026)
Korro Bio (KRRO) posted Consolidated Net Income of -$19.6 million for Q1 2026, down 121.12% on a QoQ basis from $92.9 million in Q4 2025, and up 16.09% year-over-year from -$16.9 million in Q1 2025.
Korro Bio (KRRO) Consolidated Net Income (2018 - 2026) Analysis & Trends
Korro Bio's Consolidated Net Income history runs 9 years deep, the most recent figure standing at -$19.6 million for Q1 2026.
- Quarterly Consolidated Net Income rose 16.09% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.4 million (up 852.88% YoY) and the FY2025 annual result came in at $25.7 million, up 31807.41% from the prior year.
- Consolidated Net Income was -$19.6 million for Q1 2026 at Korro Bio, down from $92.9 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $92.9 million in Q4 2025 and bottomed at -$25.8 million in Q2 2025.
- A 5-year average of -$7.8 million and a median of -$19.6 million in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2023 — Consolidated Net Income tumbled 511.02% — and 2024, when it jumped 345.03%.
- Korro Bio's Consolidated Net Income stood at $6.2 million in 2022, then tumbled by 511.02% to -$25.4 million in 2023, then soared by 345.03% to $62.3 million in 2024, then soared by 49.12% to $92.9 million in 2025, then sank by 121.12% to -$19.6 million in 2026.
- Business Quant data shows KRRO's Consolidated Net Income at -$19.6 million in Q1 2026, $92.9 million in Q4 2025, and -$18.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Korro Bio | 120.63 Mn | 6.66 Mn | - | -19.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | 92.90 Mn |
| Sep 30, 2025 | -18.06 Mn |
| Jun 30, 2025 | -25.77 Mn |
| Mar 31, 2025 | -23.39 Mn |
| Dec 31, 2024 | 62.30 Mn |
| Sep 30, 2024 | -21.00 Mn |
| Jun 30, 2024 | -21.83 Mn |
| Mar 31, 2024 | -19.56 Mn |
| Dec 31, 2023 | -25.43 Mn |
| Sep 30, 2023 | -18.49 Mn |
| Jun 30, 2023 | -17.65 Mn |
| Mar 31, 2023 | -19.61 Mn |
| Dec 31, 2022 | 6.19 Mn |
| Sep 30, 2022 | -19.55 Mn |
| Jun 30, 2022 | -21.29 Mn |
| Mar 31, 2022 | -23.39 Mn |
| Dec 31, 2021 | -21.50 Mn |
| Sep 30, 2021 | -25.16 Mn |
| Jun 30, 2021 | -17.66 Mn |